Volume 9, Issue 2 (Vol.9 No.2 Jul 2020)                   rbmb.net 2020, 9(2): 156-162 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Beikmohammadi H, Pouladi I, Zolfaghari M R, Niakan M. The Prevalence of 23S rRNA Mutations in ML-Resistant M. pneumoniae Isolates to Clarithromycin in Patients with Respiratory Infections. rbmb.net. 2020; 9 (2) :156-162
URL: http://rbmb.net/article-1-462-en.html
Department of Medical Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran
Abstract:   (278 Views)
Background: Mycoplasma pneumoniae is one of the widespread causes of community-acquired pneumonia (CAP). Over recent years, the widespread use of macrolides has led to the emergence of macrolide-resistant M. pneumoniae (MRMP) resulted from mutations at specific positions of domain V of the 23S rRNA gene.
 
Methods: We collected 100 samples of throat swabs from patients with respiratory infections. After extraction of DNA from bacterial cell cultured in PPLO broth media using Roche kit (Germany), the PCR was performed on specific samples of M. pneumoniae using specific primers for 23S rRNA gene. Afterwards, for positive samples, minimum inhibitory concentration (MIC) was determined using the broth microdilution with Clarithromycin. Finally, the PCR product was sequenced to detect mutations related to macrolide resistance in domain V of 23S rRNA.
 
Results: According to the analysis of the sequenced PCR product of M. pneumoniae 23S rRNA gene using Clustalw2 online software, one of the samples were shown to have a mutation at A2431G and G2491A positions. The MIC measurement also revealed that all isolates were sensitive to Clarithromycin, and there was no macrolide resistance to Clarithromycin in all isolates.
 
Conclusion: Sequence analysis of the 23S rRNA gene in M. pneumoniae, revealed no macrolide resistance of M. pneumoniae to Clarithromycin. Thus, the use of these antibiotics should be restricted to prevent the development of macrolide-resistant M. pneumoniae in Iran.
Full-Text [PDF 601 kb]   (100 Downloads)    
Type of Article: Original Article | Subject: Microbiology
Received: 2020/02/9 | Accepted: 2020/06/25 | Published: 2020/10/7

References
1. Eshaghi A, Memari N, Tang P, Olsha R, Farrell DJ, Low DE, et al. Macrolide-resistant Mycoplasma pneumoniae in humans, Ontario, Canada, 2010-2011. Emerg Infect Dis. 2013;19(9). [DOI:10.3201/eid1909.121466] [PMID] [PMCID]
2. Meyer Sauteura P, Bleischa B, Voitb A, Maurerb F, Rellya C, Berger C, et al. Survey of macrolide-resistant Mycoplasma pneumoniae in children with community-acquired pneumonia in Switzerland. Swiss Med Wkly. 2014;144:w14041. [DOI:10.4414/smw.2014.14041]
3. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, et al. Surveillance of Macrolide-Resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob Agents Chemother.2013;57(3):1521-1523. [DOI:10.1128/AAC.02060-12] [PMID] [PMCID]
4. Babaei Z, Pouladi I, Ashtari A, Azimi G, Niakan M. The Prevalence of Atypical Pneumonia Caused by Mycoplasma pneumoniae (P1 gene) in Patients with Respiratory Infections by Culture and Molecular PCR Methods in Tehran, Iran. Jundishapur Journal of Microbiology. 2019; 12(11):e84174. [DOI:10.5812/jjm.84174]
5. Song Q, Xu B, Shen K. Effects of bacterial and viral co-infections of mycoplasma pneumoniae pneumonia in children: analysis report from Beijing Children's Hospital between 2010 and 2014. Int J Clin Exp Med. 2015;8(9):15666-74.
6. Zhang Y, Mei S, Zhou Y, Yang D, Pan T, Chen Z, et al. TIPE2 negatively regulates mycoplasma pneumonia-triggered immune response via MAPK signaling pathway. 1ScIentIfIc RepoRts.2017;7(1):13319. [DOI:10.1038/s41598-017-13825-y] [PMID] [PMCID]
7. Zhou Y, Zhang Y, Sheng Y, Zhang L, Shen Z, Chen Z. More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2014;58(2):1034-8. [DOI:10.1128/AAC.01806-13] [PMID] [PMCID]
8. Youn YS, Lee SC, Rhim JW, Shin MS, Kang JH, Lee KY. Early Additional Immune-Modulators for Mycoplasma pneumoniae Pneumonia in Children: An Observation Study. Infect Chemother. 2014;46(4):239-47. [DOI:10.3947/ic.2014.46.4.239] [PMID] [PMCID]
9. Meyer Sauteur P, Unger W, Nadal D, Berger C, Vink C, Rossum A. Infection with and Carriage of Mycoplasma pneumoniae in Children. Front Microbiol.2016;7:329. [DOI:10.3389/fmicb.2016.00329] [PMID] [PMCID]
10. Kawai Y, Miyashita N, Kubo M, Akaike H, Kato A, Nishizawa Y, et al. Nationwide Surveillance of Macrolide-Resistant Mycoplasma pneumoniae Infection in Pediatric Patients. Antimicrob Agents Chemother.2013;57(8):4046-4049. [DOI:10.1128/AAC.00663-13] [PMID] [PMCID]
11. Saraya T. Mycoplasma pneumoniae infection: Basics. J Gen Fam Med. 2017;18(3):118-125. [DOI:10.1002/jgf2.15] [PMID] [PMCID]
12. Izumikawa K, Izumikawa K, Takazono T, Kosai K, Morinaga Y, Nakamura S, et al. Clinical features, risk factors and treatment of fulminant Mycoplasma pneumoniae pneumonia: a review of the Japanese literature. J Infect Chemother. 2014;20:181-5. [DOI:10.1016/j.jiac.2013.09.009] [PMID]
13. Valentine-King MA, Cisneros K, James MO, Huigens RW 3rd, Brown MB. Turning the Tide against Antibiotic Resistance by Evaluating Novel, Halogenated Phenazine, Quinoline, and NH125 Compounds against Ureaplasma Species Clinical Isolates and Mycoplasma Type Strains. Antimicrob Agents Chemother. 2019;63(3):e02265-18. [DOI:10.1128/AAC.02265-18] [PMID] [PMCID]
14. Lucier TS, Heitzman K, Liu SK, Hu PC, et al. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1995;39(12): 2770-3. [DOI:10.1128/AAC.39.12.2770] [PMID] [PMCID]
15. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, et al. Antimicrobial Susceptibility of Mycoplasma pneumoniae Isolates and Molecular Analysis of Macrolide-Resistant Strains from Shanghai, China. Antimicrob Agents Chemother. 2009;53(5):2160-2. [DOI:10.1128/AAC.01684-08] [PMID] [PMCID]
16. Golmohammadi R, Ataee R A, Alishiri G H, Mirnejad R, Najafi A, Tate M, et al. Molecular Diagnosis of Mycoplasma pneumoniae in Synovial Fluid of Rheumatoid Arthritis Patients. Iran J Med Microbiol. 2014;8(1):1-8.
17. Liu X, Jiang Y, Chen X, Li J, Shi D, Xin D. Drug Resistance Mechanisms of Mycoplasma pneumoniae to Macrolide Antibiotics. Biomed Res Int. 2014;2014:1-7. https://doi.org/10.1155/2014/731565 https://doi.org/10.1155/2014/937429 https://doi.org/10.1155/2014/470393 https://doi.org/10.1155/2014/319351 https://doi.org/10.1155/2014/415375 https://doi.org/10.1155/2014/137049 https://doi.org/10.1155/2014/473823 https://doi.org/10.1155/2014/379090 https://doi.org/10.1155/2014/637308 https://doi.org/10.1155/2014/634281 https://doi.org/10.1155/2014/619465 https://doi.org/10.1155/2014/627380 https://doi.org/10.1155/2014/909657 https://doi.org/10.1155/2014/902842 [DOI:10.1155/2014/836025] [PMID] [PMCID]
18. Hong JH, Chun JK, Uh Y, Oh KJ, Kim J, Yoon KJ. Two Cases of Mycoplasma pneumoniae Pneumonia with A2063G Mutation in the 23S rRNA Gene in Siblings. Ann Lab Med 2013; 33(1):65-8. [DOI:10.3343/alm.2013.33.1.65] [PMID] [PMCID]
19. Sharifi S, Ghotaslo R, Aki MT, Soroush MH, Ansarian Kh, Shabanpour J, et al. Identification of respiratory infections caused by Mycoplasma pneumoniae with three methods of cultivation, ELISA and PCR. Medical Journal of Tabriz University. 2011; 33(3): 36-41.
20. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008;52(1):348-50. [DOI:10.1128/AAC.00779-07] [PMID] [PMCID]
21. Lin C, Li S, Sun H, Zhao H, Feng Y, Cao L, et al. Nested PCR-linked capillary electrophoresis and single-strand conformation polymorphisms for detection of macrolide-resistant Mycoplasma pneumoniae in Beijing, China. J Clin Microbiol. 2010;48(12):4567-72. [DOI:10.1128/JCM.00400-10] [PMID] [PMCID]
22. Morozumi M, Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J Infect Chemother. 2010;16(2):78-86. [DOI:10.1007/s10156-009-0021-4] [PMID]
23. Brown RJ, Macfarlane-Smith L, Phillips S, Chalker VJ, et al. Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015. Euro Surveill. 2015;20(48):30078. [DOI:10.2807/1560-7917.ES.2015.20.48.30078] [PMID]
24. Haruki K, Tomoyuki T, Ayano I, Tsuyoshi S, Tomoo F. Characteristics of hospitalized children infected with macrolide-resistant Mycoplasma pneumonia brazj infectdis.2014;18(3):294-299. [DOI:10.1016/j.bjid.2013.09.004] [PMID]
25. Zhou Z, Li X, Chen X, Luo F, Pan C, Zheng X, et al. Macrolide-Resistant Mycoplasma pneumoniae in Adults in Zhejiang, China Antimicrob Agents Chemother. 2015;59(2):1048-51. [DOI:10.1128/AAC.04308-14] [PMID] [PMCID]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb